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Objective: To determine the prevalence of raised ALT, common causes, and associated fetomaternal morbidity in 
pregnant mothers presenting, at cantonment general hospital Rawalpindi 
Materials and Methods: This was a cross-sectional study conducted at cantonment general hospital Rawalpindi 
from July 2016 till June 2017.  
Results: Out of 1924 women, 102 were identified with raised ALT making a prevalence of 5.3%. Sixty-one (59.8%) 
were booked. The hypertensive group which included severe preeclampsia, chronic hypertension with 
superimposed preeclampsia/eclampsia were 55 (53.9%), intrahepatic cholestasis of pregnancy(ICP) 32 (31.7%), 
acute viral hepatitis 9 (8.8%), Acute fatty liver of pregnancy(AFLP) 2 (1.96%), and unknown cause in 4 (3.92%). 
Mean ALT levels were 54.1 ± 6.94, 71.28 ± 23.25, 84.22 ± 27.82, 231.5 ± 47.37 respectively. In four cases no 
definitive cause could be identified with the available tests were labeled as an unknown group, having a mean 
ALT level of 79.25 ± 10.07. (p=0.01).  
Term delivery occurred in 71 (69.6%), while 31 (30.39%) were preterm. There was one termination of pregnancy. 
Vaginal birth occurred in 42 (42.2%), and 53 (51.9%) underwent emergency cesarean. There was one peripartum 
hysterectomy. Meconium stain of liquor was 19 (18.6%). The birth weight of most babies 73 (71.5%) was between 
2-3 kilograms only three were ≤ 1 kilograms. 
Eight cases of postpartum hemorrhage, three maternal deaths, and six perinatal/early neonatal deaths were 
observed. 
Conclusion: Raised ALT in pregnancy leads to increased fetomaternal complications. Severe preeclampsia and 
obstetric cholestasis were the commonest causes. Women of younger age groups were having acute viral hepatitis. 
Timely recognition and diagnosis are essential to institute appropriate management strategies. 
Keywords: Liver dysfunction, pre-eclampsia, acute fatty liver of pregnancy, cholestasis of pregnancy. 
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Introduction 
 
Liver function tests (LFTS) are measured clinically as a 
biomarker for liver health. Alanine amino 
transaminase (ALT) is a transaminase enzyme is found 
in plasma, various body tissues, and mostly the liver. 
Hepatic damage causes the release of these 
intracellular enzymes, leading to raised levels. 
Interpretation of abnormal liver function tests is 
crucial, considering the widespread maternal adaptive 
response to an ongoing pregnancy. According to study 
pregnancy, related liver dysfunctions are reported to 
affect 3% of pregnancies.1 Gestational hypertensive 
disorders, acute fatty liver of pregnancy, intrahepatic 
cholestasis of pregnancy(ICP) are the major causes of 
liver derangements.2 
Hypertensive disorders (Preeclampsia/eclampsia) are 
recognized causes of the maternal mortality rate of 
15.5% according to a Turkish study.3 Increasing 
number of obstetric patients are admitted to intensive 
care units due to complications of preeclampsia.4 A 
multicentre trial in china showed 58.7% of obstetric 
patients in intensive care units had pregnancy-related 
hypertensive disorders.5 
Our Pakistani study also reported the profound effect 
of preeclampsia on liver function tests when compared 
to normal pregnancies. The mean ALT was 55.81 ± 
31.93 compared to control 15.22 ± 3.30.6 HELP 
syndrome (hemolysis, elevated liver enzymes, low 
platelet) is a serious condition with a high rate of 
maternal mortality. Disseminated intravascular 
coagulation(DIC), acute renal failure, and major 
postpartum hemorrhage (PPH)  are the feared 
complicatons7 
The incidence of ICP is also high compared to the 
other populations. According to our local study it 
affects around 3.1% of our obstetric patients.8 Patients 
with high ALT are at 3.54 fold increased risk of 
adverse perinatal outcome. Potential fetal risks include 
iatrogenic /spontaneous preterm birth, meconium, 
and fetal death.9 Ursodeoxycholic acid(UDCA) has 
been shown to improve pruritis and liver function 
tests 10,11. Early induction of labor after 37 weeks, can 
cause a major reduction in the stillbirth rate.12 
Acute Viral infections such as hepatitis A, B, C, and E 
are unfortunately very prevalent in our country. 
According to our Pakistani study vertical transmission 
of Hepatitis B and C as the mode of exposure 
accounted for one-quarter of children under five years 
of age and the majority (72.5%) occurred in Punjab 
province.13 Another local study showed Hepatitis E 
(53.8%), Hepatitis B (17.3%), Hepatitis C in 7 (13.5%) 
HELLP syndrome in (13.5%), and Acute fatty liver of 
pregnancy (AFLP) in (3.57%) cases. Maternal mortality 
of (28.8%) and fetal mortality (77%).14 In chronic liver 
disease, liver function tests may not worsen during 
pregnancy. However, in chronic hepatitis B, flares in 
ALT (99-2522U/L) were seen in 6% during pregnancy 
and 10% within three months after delivery.15 An 
Indian study showed the study frequency of chronic 
liver disease in pregnancy (0.4%), hepatic 
decompensation in 16%. A live birth rate of 76% was 
being better and complications such as variceal 
bleeding or decompensation of liver disease were less 
common than previously reported.16 
Acute Fatty liver of pregnancy (AFLP) is a rare but 
life-threatening emergency, characterized by 
microvesicular fatty infiltration of the liver, attributed 
to defect in mitochondrial beta-oxidation of fatty 
acids.17 Raised bilirubin, transaminase, and 
coagulopathy occurring in 100%, hypoglycemia in 
53%.18 
Liver dysfunction in pregnancy with markedly raised 
transaminase can lead to a severe adverse 
fetomaternal outcome. Early diagnosis and prompt 
management can markedly improve fetomaternal 
morbidity and mortality. 
 
Materials and Methods 
 
This cross-sectional study was conducted at 
Cantonment general hospital Rawalpindi from July 
2016 till February 2017. 
We recruited our pregnant patients whose ages ranged 
from 17-36 years, parity from 0-5, no history of prior 
cesarean delivery, with raised ALT using a cut-off 
value of 45 IU/L. Only those cases that had 
persistently raised levels at least on two or more 
occasions on serial monitoring were included. 
Cases of chronic liver disease and chronic hepatitis, 
alcoholism, drug-induced hepatic dysfunction, 
hyperemesis gravidarum, and autoimmune causes 
were not included. 
The decision for induction, delivery, termination, etc 
was purely based on standard obstetric indications, 
and no upper limit of ALT was defined for any 
intervention. 
Each case was analyzed in detail, regarding maternal 
demographic characteristics (age, parity, booking 
status), the mean level of ALT, gestational age at initial 
diagnosis, the possible cause of derangement in ALT, 
mode and time of delivery, the incidence of meconium 
staining of liquor, birth weight, maternal morbidity 
mortality, perinatal /early neonatal deaths. 
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The collected data was analyzed using Statistical 
Package for Social Sciences version 20. One way 
Anova, with a Post hoc test (welch’s test) was applied 





Out of 1924 women delivered during the study period, 
we found 102 were having raised ALT levels making a 
prevalence of 5.3%. Their ages ranged from 17-36 
years, and parity from 0-5. We found that younger 
women and low parity were at risk as 92 (90.1%) 
women below 31 years of age, and 86 (84.3%) women 
had parity between 0-3. 
Gestational hypertensive disorders affected 55 (53.9%), 
mean ALT was 54.10 ± 6.94, presented at a mean 
gestational age of 35.5 weeks, and delivered at a mean 
gestational age of 36.8 weeks. Headache was the 
predominant symptom, uncontrolled blood pressure, 
vertigo, and visual symptoms. There were two cases of 
seizures. This group had the highest emergency 
cesarean section rate. Out of 53 emergency cesarean 
sections, 28 (52.8% of total emergency cesarean 
sections) were performed in this group, out of which 9 
were preterm. Two of maternal deaths and three 
fetal/early neonatal deaths were observed in this 
group. One peripartum hysterectomy due to 
postpartum hemorrhage was performed in this group. 
ICP was found in 32 (31.7%), with a mean ALT level of 
71.28 ± 23.25. Pruritis was the chief complaint. One 
patient reported the recurrence of cholestasis in her all 
three pregnancies. One intrauterine fetal death was 
observed in this group. Em LSCS were 16, the main 
indications were failed induction, fetal distress, and 
meconium. 
Acute viral hepatitis was seen in 9 (8.8%), five were 
having acute hepatitis B; three had hepatitis E, and one 
hepatitis A viral infection. THE mean ALT level being 
84.22 ± 27.82, women in this group were younger 
mean age 22.55 ± 3.04, presented in early pregnancy 
mean gestational age at diagnosis was 29.08 weeks. 
Nausea and abdominal pain were the main 
complaints. One termination of pregnancy was done 
due to hepatitis E infection with the worsening of 
maternal symptoms and liver dysfunction. There were 
two emergency cesarean for fetomaternal indication.  
We had only two cases of AFLP (1.96%), who 
presented at a mean gestational age of 35.7 weeks. 
Mean ALT was highest in this group 231.5 ± 47.37. 
Unfortunately, two fetal deaths and one maternal 
death occurred in this group. 
In four patients the cause of persistently raised ALT 
could not be explained with available investigations in 
our hospital and was labeled as the unknown cause 
group. However, no significant feto-maternal 
morbidity was seen except one case of the meconium 
stain of liquor and emergency cesarean. 
There were 8 cases of postpartum hemorrhage, but 4 
patients required extensive blood transfusion(>6 units) 
and blood products. Eighteen women were admitted 
to the intensive care unit (ICU) for monitoring and 
surveillance. Nine stayed for 7 days or more. 
Meconium stain of liquor was seen in 19 (18.6%), out 
of which 9 (8.8%) were in ICP, 4 (3.92%) inactive viral 
hepatitis, 3 (2.9%) in hypertensive, 2 (1.96%) in AFLP 1 
(0.98%) in an unknown group. 
The birth weight of three babies was less than 1 kg, 73 
were between 2-3 kg, 18 were between 3-3.5 kg, and 7 
were above 3.5 kg. Twenty-three babies were retained 
in the Neonatal intensive care unit for observation, 
seventeen were admitted. However, only five remain 
stayed for 7 days or more. 
Six perinatal/early neonatal deaths were reported, 
three in the hypertensive group, two in AFLP, and one 
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Table 1: Gender and age distribution of subjects  
Group N=102 Mean ALT Std deviation 
Preeclampsia/eclampsia 55 54.10 6.94 
ICP 32 71.28 23.37 
Acute viral hepatitis 9 84.22 27.82 
AFLP 2 231.50 47.37 
Unknown cause 4 79.25 10.07 
Outcome: Mean ALT Levels   
P=0.01 
 
Table 2: Mean, the standard deviation for age, parity, gestational age at diagnosis and delivery 





























































Table 3:  Clinical presentation 
Complain/symptom Frequency Percentage 
 Headache 27 26.5 
visual/vertigo 12 11.8 
uncontrolled B.P 10 9.8 
Decreased fetal movements  12 11.8 
Abdominal  pain 9 8.8 
nausea/vomiting 9 8.8 
abnormal bleeding 6 5.9 
Pruritis 15 14.7 
Seizures 2 2.0 
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Table 4:  Maternal morbidity and mortality 
Group Maternal morbidity    Maternal mortality 
















               Nil 
Acute viral hepatitis EmLscs 
TOP 
3                Nil 
Unknown cause EmLscs 1                Nil 
TOP= Termination of pregnancy 
 
Table 5:  Fetal morbidity and mortality 
Group Meconium stain Fetal mortality 
ICP 9 (8.8%) 1 
Acute viral hepatitis 4 (3.92%) Nil 
Preeclampsia/eclampsia 3 (2.9%) 3 
AFLP 2 (1.96%) 2 




Our study showed that ALT was raised in 5.3% 
(102/1924) women using a cut-off value of 45 IU/L. 
Raised levels of Aspartate aminotransaminase (AST) 
are modestly predictors of adverse maternal outcomes.  
A study conducted in Bangladesh Mondal BR, Ahmed 
S and et al showed mean levels of total bilirubin and 
ALT was found significantly high in both 
preeclampsia and eclampsia group as compared to 
controls.19 Kojic R  and et al found absolute magnitude 
of AST, ALT, and Lactate dehydrogenase (LDH) as 
predictor of adverse maternal complications(AST: 
ROC AUC 0.73 [95% CI 0.67 to 0.97]; ALT: ROC AUC 
0.73 [95% CI 0.67 to 0.79]; LDH: ROC AUC 0.74 [95% 
CI 0.68 to 0.81]).20 
Elad mei Dan et al found  ALT level of 50 IU/L having 
a sensitivity of 3.3% (despite a specificity of 97%) in 
predicting severe preeclampsia.21 Turkmen GG et al 
have shown mean ALT, AST, and bile acids are 
significantly raised in the cholestasis group than the 
control.22 Our local study using ALT  cut off level of 
95IU/L level to predict adverse perinatal outcomes in 
intrahepatic cholestasis of pregnancy found a 
sensitivity of 76.47% and specificity of 78.8%.23 
Kondrackiene J, Zalinkevicius R et al showed using the 
cut-off value for ALT (31 IU/L) results in an increase 
of sensitivity to 92.2% vs 90.1% in diagnosing  ICP.24 
Early-onset ICP patients presented with more 
worsening symptoms, leading to more premature 
deliveries and fetal distress. However difference in 
mean ALT levels in early-onset cholestasis 159 ± 50, 
and late-onset cholestasis 142 ± 52 U/L was not 
statistically significant (p>0.05).25  
Our study had certain limitations. Our inferences 
depend on hospital record, their accuracy about 
diagnosis and management, and records on birth 
certificates and discharge forms. We tried our best to 
countercheck and recheck to minimize the bias. 
Secondly, the number of cases for some groups was 
very small e.g. AFLP. We used ANOVA with post hoc 
Welch’s correction to find the p-value.  
We could not address the impact of chronic liver 
disease on ALT during pregnancy. Most of our 
obstetric patients do not maintain their previous 
antenatal records, so we cannot compare from 
previous ALT levels. Secondly, although screening for 
viral hepatitis is performed in our hospitals but liver 
function tests such as bilirubin, ALT, AST, LDH are 
not done as a routine unless clinically indicated. So 
only acute cases with clinical features were recruited. 
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Cases of hyperemesis gravidarim, alcoholism, drug-
induced abnormality in liver function tests, and 




AFLP cases presented with the highest ALT levels. 
Severe pre-eclampsia/eclampsia affected the majority 
of our patients with high fetomaternal morbidity when 
compared to the cholestasis and viral hepatitis 
patients. While younger women were having viral 
hepatitis. Early diagnosis of the cause and prompt 
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